Lemme GLP-1 Daily Review: Does Kourtney Kardashian's Supplement Work?

Lemme GLP-1 Daily is a capsule from Lemme, the supplement brand co-founded by Kourtney Kardashian Barker. It is marketed around the most searched-for term in weight loss right now — GLP-1, the appetite hormone that drugs like Ozempic, Wegovy and Zepbound imitate at pharmacological strength — and it has the celebrity reach to put that name in front of millions of people. So we did what we do with every product on this site: we set the marketing aside and read what is actually in the bottle and what those ingredients have actually done in human trials. The gap between the name and the evidence is the whole story.

Here is the short version, stated plainly so no one can miss it: Lemme GLP-1 Daily contains no GLP-1 drug and no semaglutide, tirzepatide, or any prescription medicine of any kind. It is a botanical supplement. Its three named actives — Eriomin lemon-fruit extract, Supresa saffron, and Morosil red-orange extract — each have some human evidence, but the effects are modest, measured on markers like blood sugar, snacking and waistline, and nothing in the data resembles the 15%-of-body-weight loss the actual GLP-1 drugs produce. If you came here asking whether this is "Ozempic in a capsule," the honest answer is no, and it is not close.

What's actually in the bottle

Lemme GLP-1 Daily is built around three branded, standardized botanical extracts. Understanding the product means understanding what each one is and what it has been tested for — because the trials behind these ingredients are real, just much smaller in effect than the name implies.

Eriomin (lemon-fruit flavonoids). This is the ingredient that earns the "GLP-1" in the name. Eriomin is a standardized lemon-flavonoid extract whose main active is eriocitrin. In a crossover randomized clinical trial in people with prediabetes, Eriomin reduced blood glucose and was reported to increase glucagon-like peptide-1 — roughly a 17% rise in GLP-1 — alongside lower inflammation¹. An earlier double-blind randomized controlled trial in prediabetic adults found Eriomin lowered fasting glucose and helped reverse the prediabetes state in a meaningful share of participants over 12 weeks², and a later trial showed it shifted the gut microbiome in prediabetes³. This is the most legitimate piece of the formula — but read it precisely: the GLP-1 finding is a blood-marker effect in prediabetics over about 12 weeks, not a demonstration that the finished Lemme product makes healthy people lose weight.

Supresa (saffron extract). Saffron, branded here as Supresa, has a single well-known supportive trial: an eight-week randomized placebo-controlled study of a saffron extract (marketed elsewhere as Satiereal) in mildly overweight women, which found it reduced between-meal snacking and increased self-reported satiety versus placebo⁴. It is a real, plausibly serotonin-related appetite nudge — but it is one small, short study, and the actual weight difference it produced was barely measurable. We dig into exactly how thin that evidence is in our saffron extract appetite-suppressant review.

Morosil (Moro red-orange extract). Morosil is a standardized extract of Moro blood oranges (a Citrus sinensis variety). Its supporting trial is a randomized, double-blind, placebo-controlled study in overweight-but-healthy adults that reported reductions in body weight and waist and hip circumference over the study period versus placebo⁵; an earlier Moro orange-juice study also reported modest weight-management signals⁶. The effect is real in that one trial but modest, and the broader independent literature on red-orange complexes is thinner than the marketing suggests.

The name is doing a lot of work

Put the label next to the data and the mismatch is clean. The product is called "GLP-1 Daily," and exactly one of its three ingredients has a GLP-1 finding at all — Eriomin's ~17% GLP-1 rise in prediabetics¹. That number sounds impressive until you place it beside what GLP-1 drugs do. A receptor agonist like semaglutide doesn't nudge your own GLP-1 up by a sixth; it floods the GLP-1 receptor at supraphysiologic levels, which is why the pivotal STEP 1 trial produced about 15% mean body-weight loss over 68 weeks⁷. A modest rise in a hormone marker and a drug that saturates the same receptor are not the same category of intervention, and no honest reading of the data treats them as interchangeable.

It is also worth being precise about what each ingredient was tested for. Eriomin's strong data is a glucose/GLP-1 effect in prediabetics — a metabolic-marker outcome, not a weight-loss outcome. Saffron's data is a snacking/satiety effect, not measured weight loss. Morosil's data is the only one of the three that directly measured body weight and waist, and even there the effect is modest and rests largely on one trial. So the formula is not three weight-loss ingredients stacked together; it is one glucose-marker ingredient, one appetite-behavior ingredient, and one modest waistline ingredient — each from its own small evidence base, none individually close to a medication, and the combination never tested as a finished product in a published weight-loss trial.

What the evidence does and doesn't support

None of this makes Lemme GLP-1 Daily a scam. Eriomin is genuinely one of the better-studied botanicals for glycemic markers, the saffron snacking trial is a real randomized result, and Morosil has a body-weight RCT in its corner — that is more human evidence than most celebrity supplements carry. The problem is purely one of magnitude and framing: the product borrows the name of a class of medications that work an order of magnitude more powerfully, and the implied promise (drug-like appetite suppression and weight loss) is not what the underlying studies measured or found.

There is also a structural caveat that applies to nearly every multi-ingredient botanical: the human trials behind Eriomin, saffron and Morosil each tested a specific dose of a single extract, often in a specific population (prediabetics, overweight women). A capsule that combines all three may or may not deliver each ingredient at its studied dose, and the finished Lemme formula has not been run through its own published randomized weight-loss trial. "Each ingredient has a study" is not the same as "this product has a study," and that distinction matters for your expectations. This is the exact pattern we flag across the category in our review of GLP-1 booster supplements — a product that "supports GLP-1" on a marketing slide is selling you the mechanism, not the medication-grade result.

How to think about buying it

As of 2026 Lemme GLP-1 Daily sells for roughly $60–$72 for a one-month supply, or somewhat less on subscription — premium pricing for a botanical supplement, which makes the evidence question a real one for your wallet. If you want to try it, set expectations that match the data rather than the name. A defensible case exists if you have prediabetes or mild blood-sugar concerns and want a reasonably well-studied lemon-flavonoid (Eriomin) with a saffron snacking nudge attached, and you can absorb the price. Treat any scale movement as a pleasant surprise layered on top of diet, protein, fiber and sleep — not as the engine of weight loss.

What you should not do is buy it expecting it to stand in for, or work like, a prescription GLP-1. If meaningful, drug-like weight loss is the goal, the honest magnitude comparison is laid out in our supplements vs GLP-1 drugs breakdown, and the gap is roughly an order of magnitude. For the broader question of whether any over-the-counter "GLP-1" product earns its name, start with do GLP-1 supplements work?.

The bottom line

Lemme GLP-1 Daily is an honestly-formulated, premium-priced botanical built on three real but modest ingredients — Eriomin (a ~17% GLP-1 and glucose-marker effect in prediabetics), Supresa saffron (a small snacking/satiety effect), and Morosil red orange (a modest body-weight effect in one RCT). What it is not is a GLP-1 drug, a semaglutide alternative, or anything that produces Ozempic-like results; it contains no medication, and no published trial has tested the finished product for weight loss. It borrows one of the most powerful names in modern medicine to sell a supplement whose evidence, while better than most, sits an order of magnitude below the drugs it evokes. For where this lands among everything we have vetted, see our best natural GLP-1 supplements guide, and for the full category framework, start with our pillar, 'natural GLP-1' supplements: what the evidence shows.